A moxibustion combined pharmaceutical composition for treating lung cancer cancer-related fatigue and application thereof

Abstract

The application discloses a medicine-moxibustion combined medicine composition for treating lung cancer cancer-induced fatigue and application thereof. The medicine-moxibustion combined medicine composition can effectively solve the problem of oral and navel moxibustion combined medicine for treating lung cancer cancer-induced fatigue. The medicine-moxibustion combined medicine composition comprises a first unit oral traditional Chinese medicine composition and a second unit navel moxibustion traditional Chinese medicine composition. The first unit oral traditional Chinese medicine composition is prepared from Chinese yam, radix codonopsis, poria cocos, rhizoma atractylodis macrocephalae, ganoderma lucidum, dried tangerine or orange peel, lablab bean, lotus seed, prepared licorice, amomum villosum, coix seed and platycodon grandiflorum, is soaked in water, is boiled with a strong fire, is boiled with a weak fire, is filtered, is concentrated under reduced pressure, is dried, is crushed, is uniformly prepared into soft material by adding an auxiliary material and using ethanol as a wetting agent, is sieved and granulated, is dried, is whole-granulated, and is packed, and the second unit navel moxibustion traditional Chinese medicine composition is prepared from astragalus root, rhizoma atractylodis macrocephalae, wind-preventing herb, galangal, dried ginger, costus root, dried tangerine or orange peel, agarwood, frankincense and boswellia, is uniformly prepared by crushing and mixing, is rich in raw materials, is scientific and reasonable, is easy to produce and prepare, is convenient to use, is safe in medicine use, is good in curative effect, and has actual clinical application value.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine, and in particular to a combination of moxibustion and medicated drug composition for treating cancer-related fatigue in lung cancer and its application. Background Technology

[0002] Cancer-related fatigue (CRF) is a painful, persistent, subjective feeling of physical, emotional, or cognitive fatigue or exhaustion caused by cancer or a variety of factors related to cancer treatment. It is disproportionate to recent activity levels and significantly impacts the quality of life and treatment adherence of cancer patients. CRF can persist throughout the entire course of cancer treatment.

[0003] Cancer-related fatigue is the most common accompanying symptom in lung cancer patients during the course of the disease and during anti-tumor treatments such as radiotherapy, chemotherapy, immunotherapy, and targeted therapy, with an incidence rate exceeding 80%. While the increased intensity of malignant tumor treatment enhances the efficacy of anti-tumor therapy, it also significantly increases treatment-related adverse reactions, and cancer-related fatigue is a common and far-reaching accompanying symptom in clinical practice.

[0004] Currently, Western medicine interventions for CRF (cancerous fibrosis relapse) primarily focus on symptomatic support, lacking specific drugs. Traditional Chinese medicine, with its holistic approach, advocates a patient-centered approach to cancer treatment, opposing the one-sided model of simply "killing the tumor." Modern medicine lacks effective interventions for lung cancer CRF, necessitating the exploration of safe and effective integrated traditional Chinese and Western medicine treatment plans.

[0005] Traditional Chinese medicine believes that fatigue caused by lung cancer is mostly classified under the categories of "deficiency" and "weakness" in TCM theory. Its occurrence is closely related to the depletion of vital energy in the lung cancer itself and during the treatment process. The core pathogenesis is "deficiency of vital energy as the root, cancer toxin as the manifestation, a mixture of deficiency and excess, and imbalance of qi, blood, yin and yang". The disease location is mainly in the lung, spleen and kidney, involving the insufficiency of qi, blood, yin and yang, with the root being deficiency and the manifestation being excess, and a mixture of deficiency and excess.

[0006] Therefore, intervention for CRF in lung cancer should take into account the treatment goal of "living with the tumor" and focus on reducing the disease burden and economic burden of CRF caused by anti-tumor treatment. Traditional Chinese medicine has unique efficacy in treating various diseases through multiple targets. At present, there is an urgent need to research and develop safe and effective traditional Chinese medicine for lung cancer-related fatigue. Summary of the Invention

[0007] In view of the above situation and to overcome the shortcomings of the prior art, the purpose of this invention is to provide a drug-moxibustion combination drug composition for treating cancer-related fatigue in lung cancer and its application, which can effectively solve the problem of combined oral and umbilical moxibustion medication for treating cancer-related fatigue in lung cancer.

[0008] The technical solution provided by this invention is: a combined drug and moxibustion composition for treating cancer-related fatigue in lung cancer, comprising a first unit of oral Chinese medicine composition and a second unit of umbilical moxibustion Chinese medicine composition, wherein: The first unit of the oral Chinese medicine composition is made from the following raw materials by weight: 20-40g of Chinese yam, 15-30g of codonopsis, 15-30g of poria cocos, 20-40g of atractylodes macrocephala, 12-15g of ganoderma lucidum, 10-15g of tangerine peel, 10-20g of white hyacinth bean, 15-20g of lotus seed, 6-12g of prepared licorice root, 6-9g of amomum villosum, 20-30g of coix seed, and 9-15g of platycodon grandiflorus. The above raw materials are combined and added to a mixture of 5 times their weight volume of water (the weight volume refers to g for solids and mL for liquids). The mixture is then soaked for two hours and decocted over high heat. Boil the raw material in boiling water over high heat for 40 minutes, collect the filtrate, add 4 times the weight and volume of water to the residue, bring to a boil over high heat, then simmer over low heat for 30 minutes, collect the filtrate, combine the two filtrates, concentrate under reduced pressure at 50°C to prepare an extract with a relative density of 1.2, dry the extract, pulverize it into a fine powder, add excipients, the weight ratio of fine powder to excipients is 1:2, the excipients are dextrin and sugar powder in a weight ratio of 1:1, use 80% ethanol as a wetting agent, uniformly form a soft mass, granulate through a 20-mesh sieve, dry at 60°C, granulate through a 14-mesh sieve, and package to obtain the final product; The second unit of the umbilical moxibustion herbal composition is made from the following raw materials by weight: Astragalus membranaceus 15-30g, Atractylodes macrocephala 10-20g, Saposhnikovia divaricata 10-15g, Alpinia officinarum 6-12g, Zingiber officinale 6-12g, Aucklandia lappa 6-10g, Citrus reticulata 10-15g, Aquilaria sinensis 3-6g, Boswellia carterii 6-10g, and Dalbergia odorifera 6-10g. The above components are pulverized and mixed evenly to form the umbilical moxibustion powder.

[0009] The present invention relates to the application of a combination of moxibustion and pharmaceutical composition in the preparation of a drug for treating cancer-related fatigue in lung cancer and in the preparation of a medicine box for treating cancer-related fatigue in lung cancer.

[0010] This invention uses abundant raw materials, and the formulation is effectively combined according to the principal and assistant relationships of the monarch, minister, adjuvant and guide. It is scientific and reasonable, easy to produce and prepare, convenient to use, and safe to use. It takes the method of nourishing the earth to generate metal as the treatment principle, warms and unblocks the meridians, regulates qi and blood, harmonizes yin and yang, and replenishes essence and marrow. It has good effects and practical clinical application value. Detailed Implementation

[0011] The specific implementation of the present invention will be described in detail below with reference to examples and specific circumstances. Example

[0012] This invention discloses a combined medicinal and moxibustion drug composition for treating cancer-related fatigue in lung cancer, comprising a first unit of oral Chinese medicine composition and a second unit of umbilical moxibustion Chinese medicine composition, wherein: The first unit of the oral Chinese medicine composition is made from the following raw materials by weight: 30g of Chinese yam, 15g of codonopsis, 15g of poria cocos, 20g of atractylodes macrocephala, 15g of ganoderma lucidum, 15g of tangerine peel, 20g of white hyacinth bean, 15g of lotus seed, 6g of prepared licorice root, 6g of amomum villosum, 20g of coix seed, and 15g of platycodon grandiflorus. Combine the above raw materials, add 960mL of water, soak for two hours, bring to a boil over high heat, then simmer over low heat for 40 minutes. Collect the filtrate, and add 768mL of water to the dregs. Bring to a boil over high heat, then simmer over low heat for 30 minutes. Collect the filtrate, combine the two filtrates, and concentrate under reduced pressure at 50°C to prepare an extract with a relative density of 1.2. Dry the extract, pulverize it into a fine powder, and add excipients. The weight ratio of fine powder to excipients is 1:2. The excipients are dextrin and sugar powder in a weight ratio of 1:1. Use 80% ethanol as a wetting agent to uniformly form a soft mass, granulate it through a 20-mesh sieve, dry it at 60°C, granulate it through a 14-mesh sieve, and package it to obtain the final product. The second unit of the umbilical moxibustion herbal composition is made from the following raw materials by weight: Astragalus membranaceus 20g, Atractylodes macrocephala 15g, Saposhnikovia divaricata 12g, Alpinia officinarum 9g, Zingiber officinale 9g, Aucklandia lappa 8g, Citrus reticulata 12g, Aquilaria sinensis 5g, Boswellia carterii 8g, and Dalbergia odorifera 8g. The above components are pulverized and mixed evenly to form umbilical moxibustion powder. Example

[0013] This invention discloses a combined medicinal and moxibustion drug composition for treating cancer-related fatigue in lung cancer, comprising a first unit of oral Chinese medicine composition and a second unit of umbilical moxibustion Chinese medicine composition, wherein: The first unit of the oral Chinese medicine composition is made from the following raw materials by weight: 20 g of Chinese yam, 15 g of codonopsis, 20 g of poria cocos, 30 g of atractylodes macrocephala, 12 g of ganoderma lucidum, 12 g of tangerine peel, 15 g of white hyacinth bean, 15 g of lotus seed, 9 g of prepared licorice root, 9 g of amomum villosum, 30 g of coix seed, and 15 g of platycodon grandiflorus. Combine the above raw materials, add 1010 mL of water, soak for two hours, bring to a boil over high heat, then simmer over low heat for 40 minutes. Collect the filtrate, add 808 mL of water to the dregs, bring to a boil over high heat, then simmer over low heat for 30 minutes. The filtrate was collected, and the two filtrates were combined and concentrated under reduced pressure at 50°C to prepare an extract with a relative density of 1.2. The extract was dried, pulverized into a fine powder, and excipients were added. The weight ratio of the fine powder to the excipients was 1:2. The excipients were dextrin and sugar powder in a weight ratio of 1:1. Ethanol with a volume concentration of 80% was used as a wetting agent to uniformly form a soft mass. The mass was granulated through a 20-mesh sieve, dried at 60°C, granulated through a 14-mesh sieve, and packaged to obtain the final product. The second unit of the umbilical moxibustion herbal composition is made from the following raw materials by weight: Astragalus membranaceus 30g, Atractylodes macrocephala 20g, Saposhnikovia divaricata 15g, Alpinia officinarum 12g, Zingiber officinale 12g, Aucklandia lappa 10g, Citrus reticulata 15g, Aquilaria sinensis 6g, Boswellia carterii 10g, and Dalbergia odorifera 10g. The above components are pulverized and mixed evenly to form umbilical moxibustion powder. Example

[0014] This invention discloses a combined medicinal and moxibustion drug composition for treating cancer-related fatigue in lung cancer, comprising a first unit of oral Chinese medicine composition and a second unit of umbilical moxibustion Chinese medicine composition, wherein: The first unit of the oral Chinese medicine composition is made from the following raw materials by weight: 40g of Chinese yam, 30g of codonopsis, 30g of poria cocos, 40g of atractylodes macrocephala, 15g of ganoderma lucidum, 15g of tangerine peel, 15g of white hyacinth bean, 15g of lotus seed, 9g of prepared licorice root, 9g of amomum villosum, 30g of coix seed and 15g of platycodon grandiflorus. Combine the above-mentioned raw materials, add 1315mL of water and soak for two hours, bring to a boil over high heat, simmer over low heat for 40 minutes, collect the filtrate, add 1052mL of water to the residue, bring to a boil over high heat, simmer over low heat for 30 minutes, collect the filtrate, combine the two filtrates, concentrate under reduced pressure at 50℃ to prepare an extract with a relative density of 1.2, dry the extract, pulverize it into fine powder, add excipients, the weight ratio of fine powder to excipients is 1:2, the excipients are dextrin and sugar powder in a weight ratio of 1:1, use 80% ethanol as a wetting agent, uniformly form into a soft mass, granulate through a 20-mesh sieve, dry at 60℃, granulate through a 14-mesh sieve, and package to obtain the final product; The second unit of the umbilical moxibustion herbal composition is made from the following raw materials by weight: Astragalus membranaceus 15g, Atractylodes macrocephala 10g, Saposhnikovia divaricata 10g, Alpinia galanga 6g, Zingiber officinale 6g, Aucklandia lappa 6g, Citrus reticulata 10g, Aquilaria sinensis 3g, Boswellia carterii 6g, and Dalbergia odorifera 6g. The above components are pulverized and mixed evenly to form umbilical moxibustion powder. Example

[0015] This invention discloses a combined medicinal and moxibustion drug composition for treating cancer-related fatigue in lung cancer, comprising a first unit of oral Chinese medicine composition and a second unit of umbilical moxibustion Chinese medicine composition, wherein: The first unit of the oral Chinese medicine composition is made from the following raw materials by weight: 30g of Chinese yam, 20g of codonopsis, 20g of poria cocos, 20g of stir-fried atractylodes macrocephala, 15g of ganoderma lucidum, 15g of tangerine peel, 15g of white hyacinth bean, 15g of lotus seed, 10g of amomum villosum, 30g of stir-fried coix seed, 15g of platycodon grandiflorus, and 9g of prepared licorice root. Combine the above raw materials, add 1070mL of water and soak for two hours. Bring to a boil over high heat, then simmer over low heat for 40 minutes. Collect the filtrate, and add 856mL of water to the dregs. Bring to a boil over high heat, then simmer over low heat for 30 minutes. Collect the filtrate, combine the two filtrates, and concentrate under reduced pressure at 50°C to prepare an extract with a relative density of 1.2. Dry the extract, pulverize it into a fine powder, add excipients, with a weight ratio of fine powder to excipients of 1:2. The excipients are dextrin and sugar powder in a weight ratio of 1:1. Use 80% ethanol as a wetting agent to uniformly form a soft mass, granulate it through a 20-mesh sieve, dry it at 60°C, granulate it through a 14-mesh sieve, and package it to obtain the final product. The second unit of the umbilical moxibustion herbal composition is made from the following raw materials by weight: Astragalus membranaceus 15g, Atractylodes macrocephala 20g, Saposhnikovia divaricata 10g, Alpinia officinarum 12g, Zingiber officinale 6g, Aucklandia lappa 10g, Citrus reticulata 10g, Aquilaria sinensis 6g, Boswellia carterii 6g, and Dalbergia odorifera 10g. The above components are pulverized and mixed evenly to form umbilical moxibustion powder. Example

[0016] This invention discloses a combined medicinal and moxibustion drug composition for treating cancer-related fatigue in lung cancer, comprising a first unit of oral Chinese medicine composition and a second unit of umbilical moxibustion Chinese medicine composition, wherein: The first unit of the oral Chinese medicine composition is made from the following raw materials by weight: 40g of Chinese yam, 15g of codonopsis, 30g of poria cocos, 20g of atractylodes macrocephala, 15g of ganoderma lucidum, 10g of tangerine peel, 20g of white hyacinth bean, 15g of lotus seed, 12g of prepared licorice root, 6g of amomum villosum, 30g of coix seed, and 9g of platycodon grandiflorus. Combine the above raw materials, add 1110mL of water and soak for two hours. Bring to a boil over high heat, then simmer over low heat for 40 minutes. Collect the filtrate, and add 888mL of water to the remaining dregs. Bring to a boil over high heat, then simmer over low heat for 30 minutes. Collect the filtrate, combine the two filtrates, and concentrate under reduced pressure at 50°C to prepare an extract with a relative density of 1.2. Dry the extract, pulverize it into a fine powder, and add excipients. The weight ratio of fine powder to excipients is 1:2. The excipients are dextrin and sugar powder in a weight ratio of 1:1. Use 80% ethanol as a wetting agent to uniformly form a soft mass, granulate it through a 20-mesh sieve, dry it at 60°C, granulate it through a 14-mesh sieve, and package it to obtain the final product. The second unit of the umbilical moxibustion herbal composition is made from the following raw materials by weight: Astragalus membranaceus 30g, Atractylodes macrocephala 10g, Saposhnikovia divaricata 15g, Alpinia officinarum 6g, Zingiber officinale 6g, Aucklandia lappa 6g, Citrus reticulata 15g, Aquilaria sinensis 3g, Boswellia carterii 10g and Dalbergia odorifera 6g. The above components are pulverized and mixed evenly to form umbilical moxibustion powder.

[0017] The present invention relates to the application of a combination of moxibustion and pharmaceutical composition in the preparation of a drug for treating cancer-related fatigue in lung cancer and in the preparation of a medicine box for treating cancer-related fatigue in lung cancer.

[0018] The medicine box contains: (a) The first unit of traditional Chinese medicine composition, an oral preparation containing the above-mentioned traditional Chinese medicine composition as an active ingredient; (b) The second unit of traditional Chinese medicine composition contains a moxibustion powder made from Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, Alpinia galanga, Zingiber officinale, Aucklandia lappa, Citrus reticulata, Aquilaria sinensis, Boswellia carterii and Dalbergia odorifera; (c) Instructions for use, which describe the combined use of the first unit traditional Chinese medicine composition and the second unit traditional Chinese medicine composition, wherein the second unit traditional Chinese medicine composition is used by placing the moxibustion powder on the Shenque acupoint and applying moxibustion.

[0019] The first unit of traditional Chinese medicine composition can be formulated into medically acceptable granules, pills, decoctions, or capsules according to actual needs; the second unit of traditional Chinese medicine composition can be formulated into powders, cakes, or ointments. The second unit of the traditional Chinese medicine composition also includes flour material for making dough rings, and a dough ring making method described in the instructions for use.

[0020] The instruction manual states that the dosage of the moxibustion powder is 10g each time, the moxa cone is 2cm in diameter and 2cm in height, 4 moxa cones are applied continuously, each treatment lasts for 1 hour, the moxa cake is left in place for 24 hours, treatment is performed once every 3 days, and 2 months is one course of treatment.

[0021] The compositions given in the above embodiments can be used to prepare any amount of traditional Chinese medicine as needed. The given embodiments are only for illustrating specific implementation methods of the present invention and are not intended to limit the scope of protection of the present invention. The core technology protected by the present invention is the traditional Chinese medicine composition.

[0022] In the drug combinations given above, among which: Chinese yam: Sweet in taste, neutral in nature. It enters the spleen, lung, and kidney meridians. It nourishes and benefits the kidneys, strengthens the stomach and resolves phlegm, replenishes the middle energizer and boosts qi, dispels cold wind, calms the mind, soothes the soul, and strengthens muscles and marrow.

[0023] Codonopsis pilosula: Sweet, neutral. Enters the spleen and lung meridians. Tonifies the middle energizer and replenishes qi, strengthens the spleen and benefits the lungs.

[0024] Poria cocos: Sweet, bland, and neutral. It enters the heart, spleen, and kidney meridians. It promotes diuresis and eliminates dampness, strengthens the spleen, and calms the mind.

[0025] Atractylodes macrocephala: Bitter, sweet, and warm. It enters the spleen and stomach meridians. It strengthens the spleen and replenishes qi, dries dampness and promotes diuresis, stops sweating, and calms the fetus.

[0026] Reishi mushroom: Sweet, neutral. It enters the heart, lung, liver, and kidney meridians. It replenishes qi, calms the mind, relieves cough and asthma.

[0027] Dried tangerine peel: bitter and pungent, warm in nature. It enters the spleen and lung meridians. It regulates qi, strengthens the spleen, dries dampness, and resolves phlegm.

[0028] White hyacinth bean: sweet, slightly warm. It enters the spleen and stomach meridians. It strengthens the spleen, resolves dampness, harmonizes the middle jiao, and relieves summer heat.

[0029] Lotus seeds: sweet, astringent, and neutral in nature. They enter the heart, spleen, kidney, stomach, liver, and bladder meridians. They tonify the spleen and stop diarrhea; benefit the kidneys and strengthen essence; nourish the heart and calm the mind.

[0030] Prepared licorice root: sweet, neutral. It enters the heart, lung, spleen, and stomach meridians. It tonifies the spleen and stomach, replenishes qi, and restores the pulse.

[0031] Amomum villosum: pungent and warm in nature. It enters the spleen, stomach, and kidney meridians. It resolves dampness, promotes qi circulation, warms the spleen, stops diarrhea, and calms the fetus.

[0032] Job's tears: sweet and bland, slightly cold. It enters the spleen, stomach, and lung meridians. It strengthens the spleen and eliminates dampness, relieves numbness and stops diarrhea, clears heat and drains pus.

[0033] Platycodon grandiflorus: bitter, pungent, neutral. Enters the Lung meridian. Functions to clear the lungs, soothe the throat, resolve phlegm, and drain pus.

[0034] Astragalus: Sweet, warm. Enters the lung and spleen meridians. Tonifies qi and strengthens the exterior, promotes diuresis and eliminates toxins, drains pus, and promotes wound healing and tissue regeneration.

[0035] Fangfeng (Saposhnikovia divaricata): Pungent, sweet, and warm. It enters the bladder, liver, and spleen meridians. It relieves exterior syndromes, dispels wind, eliminates dampness, and stops spasms.

[0036] Galangal: pungent and hot in nature. It enters the spleen and stomach meridians. It clears heat, relieves pain, warms the middle jiao, and stops vomiting.

[0037] Dried ginger: pungent and hot. It enters the spleen, stomach, heart, and lung meridians. It warms the middle jiao (spleen and stomach), dispels cold, restores yang, unblocks the meridians, and warms the lungs to resolve phlegm.

[0038] Costus root: It is warm in nature and has a pungent and bitter taste. It promotes qi circulation, relieves pain, strengthens the spleen, and aids digestion.

[0039] Dried tangerine peel: bitter and pungent, warm in nature. It enters the spleen and lung meridians. It regulates qi, strengthens the spleen, dries dampness, and resolves phlegm.

[0040] Agarwood: pungent, bitter, and warm in nature. It enters the spleen, stomach, and kidney meridians. It promotes qi circulation and relieves pain, warms the middle jiao and dispels cold, and relieves nausea and asthma.

[0041] Frankincense: pungent, bitter, and warm in nature. It enters the heart, liver, and spleen meridians. It invigorates blood circulation, relieves pain, reduces swelling, and promotes tissue regeneration.

[0042] Dalbergia odorifera: pungent, warm. It enters the heart and liver meridians. It invigorates blood circulation, removes blood stasis, and relieves pain.

[0043] Based on the principles of traditional Chinese medicine, the above components are arranged in a principal-secondary-principal-assistant-guide manner, with their functions interconnected and working together. In the first unit of the formula, Codonopsis pilosula, Atractylodes macrocephala, and Poria cocos are the principal herbs for invigorating qi and strengthening the spleen. The combination of these three herbs forms the core of the "Four Gentlemen Decoction," directly addressing the root cause of spleen and stomach qi deficiency. This is the foundation for the formula to invigorate qi and strengthen the spleen, nourishing the earth to generate metal. When the "earth" is strong, it can generate "metal." Dioscorea opposita, lotus seeds, and white hyacinth bean are the assistant herbs, which can invigorate spleen qi and nourish spleen yin, indirectly replenishing lung qi. When spleen yin is sufficient, lung fluids have a source. Coix seed strengthens the spleen and eliminates dampness, assisting the principal and assistant herbs in resolving dampness in the body. Amomum villosum invigorates the spleen and stomach, promotes qi circulation, resolves stagnation, and relieves chest congestion, preventing the tonifying herbs from obstructing the spleen and stomach, thus serving as an adjuvant herb. Platycodon grandiflorus promotes lung qi circulation, regulates water metabolism, and carries the herbs upwards, guiding them into the lung meridian, allowing the spleen-tonifying effect to reach the upper burner, embodying the targeted nature of "strengthening the earth to generate metal". Ganoderma lucidum tonifies qi, calms the mind, relieves cough and asthma, and strengthens the body's foundation, targeting lung cancer. Tangerine peel regulates qi, strengthens the spleen, dries dampness, and resolves phlegm. Licorice root strengthens the spleen and harmonizes the middle burner, harmonizing the herbs, thus serving as an adjuvant herb.

[0044] The second unit's formula uses Astragalus membranaceus, Atractylodes macrocephala, and Saposhnikovia divaricata as the principal herbs, replenishing the Qi of the lungs and spleen from the root, addressing the core issue of "Qi deficiency as the root cause" in cancer-related fatigue. Alpinia galanga, Zingiber officinale, Aucklandia lappa, and Citrus reticulata are used as assistant herbs, warm in nature and pungent in flavor, to warm the middle Jiao, dispel cold, regulate Qi, and promote circulation. This helps to open up the Qi mechanism in the middle Jiao, allowing the principal herbs to penetrate better and exert their effects more effectively. It also relieves symptoms of Qi stagnation associated with cancer pain, poor appetite, and fatigue. Frankincense and Dalbergia odorifera have strong aromas that can quickly stimulate nerve endings in the navel, promoting blood circulation and relieving stagnation, serving as adjuvant herbs. Agarwood guides the other herbs downwards, warms the middle Jiao, and relieves asthma, serving as guiding herbs. Modern medicine believes that the skin around the navel is thin, highly sensitive, and contains a rich vascular network, allowing for rapid absorption. Applying topical medications to the navel facilitates drug penetration, allowing the medication to reach the whole body more effectively. The Shenque acupoint is a vital point for strengthening the body and maintaining health, serving as the "general hub of the meridians and the sea of ​​Qi." Umbilical moxibustion integrates the effects of meridians, acupoints, medicine, and moxibustion, thereby achieving the effects of warming and unblocking the meridians, regulating qi and blood circulation, harmonizing yin and yang, and replenishing essence and marrow, thus achieving the effect of tonifying deficiency.

[0045] The combined use of oral medication and umbilical moxibustion is effective in treating cancer-related fatigue in lung cancer, demonstrating good efficacy, high efficiency, no toxic side effects, short treatment cycle, and no recurrence. Furthermore, trials have shown very good and beneficial technical results. Relevant experimental materials are as follows (taking Example 1 as an example): I. Criteria for Case Selection We selected 120 patients with lung cancer CRF (lung and spleen qi deficiency syndrome) admitted to the Department of Respiratory Medicine and Department of Oncology of our hospital from August 2022 to August 2023. Among them, there were 58 males and 62 females. The Shenling Powder group consisted of 21 males and 19 females, aged 42 to 75 years, with a mean age of (54.23±7.3) years. The Umbilical Moxibustion group consisted of 18 males and 22 females, aged 36 to 58 years, with a mean age of (46.6±6.5) years. The Combined Herbal Moxibustion group consisted of 19 males and 21 females, aged 39 to 69 years, with a mean age of (46.1±7.5) years. There were no statistically significant differences in the general characteristics of the above patients (P>0.05), and they were comparable.

[0046] Western medicine diagnostic criteria: Diagnostic criteria were formulated with reference to the 2021 edition of the "Chinese Medical Association Oncology Branch Clinical Diagnosis and Treatment Guidelines for Lung Cancer" and the 2018 edition of the NCCN "Guidelines for Cancer-Related Fatigue". Pathological examination confirmed lung cancer, and imaging showed solid tumor lesions. According to the diagnostic criteria for CRF proposed at the 10th International Conference on Revision of Classification of Diseases (ICD-10), fatigue symptoms recur and last for more than 2 weeks, accompanied by 5 or more of the following symptoms: ① general weakness or heaviness in the limbs; ② inability to concentrate; ③ lack of enthusiasm, low mood, and loss of interest; ④ insomnia or somnolence; ⑤ feeling that energy has not been restored after rest; ⑥ difficulty in activities; ⑦ emotional reactions such as sadness or frustration; ⑧ inability to perform previously competent daily activities; ⑨ short-term memory loss; ⑩ fatigue symptoms that do not subside for several hours.

[0047] Traditional Chinese Medicine (TCM) syndrome diagnosis criteria: Formulated with reference to the 2002 "Guiding Principles for Clinical Research of New Traditional Chinese Medicine Drugs (Trial Implementation)". Diagnostic criteria for Lung and Spleen Qi Deficiency Syndrome: ① Primary symptoms: shortness of breath, fatigue, pale or sallow complexion; ② Secondary symptoms: palpitations, insomnia, dizziness, pale lips and nails, spontaneous sweating, poor appetite; ③ Tongue and pulse: pale tongue, thin white coating, deep and thready pulse. A diagnosis can be made if 1-2 primary symptoms are present, along with 2 secondary symptoms, combined with tongue and pulse diagnosis.

[0048] Inclusion criteria: (1) Patients with pathologically confirmed lung cancer who meet the diagnostic criteria for CRF; (2) Patients who meet the TCM diagnostic criteria for lung and spleen qi deficiency syndrome; (3) Age 25–75 years; (4) Patients who have not used any treatments that enhance immune function within one month prior to treatment; (5) Patients who can cooperate with physical examinations, treatments, and the recording of scores for various indicators; (6) Expected survival > 6 months and KPS score > 60 points; (7) Patients and their families who voluntarily participate in the trial and have good compliance.

[0049] Exclusion criteria: serious primary diseases or complications such as cardiovascular and cerebrovascular diseases, abnormal liver and kidney function; use of immunomodulators or other therapies that may interfere with the research results during treatment; allergy to traditional Chinese medicine or moxibustion or hypersensitivity; special populations (pregnancy, lactation, mental illness, skin diseases or trauma).

[0050] II. Treatment Plan A randomized, controlled clinical trial design was adopted. Following the guidelines for clinical research of new traditional Chinese medicine drugs, a small-sample exploratory clinical study was conducted in Phase II. The 120 enrolled patients were randomly assigned to three groups using a block randomization method. The randomization protocol was generated using the SAS program, and the patients were randomly divided into three groups: the Shenling Powder group (n=40), the Umbilical Moxibustion group (n=40), and the Combined Formula and Moxibustion group (Shenling Powder combined with Umbilical Moxibustion) (n=40).

[0051] Specifically: ① Shenling Powder Group (i.e., only the first unit of oral Chinese medicine): conventional Western medicine treatment + Shenling Powder granules, twice a day, once in the morning and once in the evening, 12-15g each time, taken with warm water; ② Umbilical moxibustion group (i.e., only the second unit of Chinese medicine umbilical moxibustion): conventional Western medicine treatment + umbilical moxibustion powder, once every 3 days, each time take 10g of powder, wrap it in a medicated cloth, apply it to the navel, moxibustion for one hour, and then leave it on the navel for 24 hours.

[0052] ③ Combined drug group: conventional Western medicine treatment + Shenling San granules combined with umbilical moxibustion powder, with the same usage and dosage as above.

[0053] The efficacy of each of the above groups was statistically analyzed over two months.

[0054] III. Efficacy Evaluation Criteria 3.1 Observation Indicators Key indicators: Traditional Chinese Medicine syndrome score, Piper fatigue scale, and Cancer-related fatigue scale (CFS); Secondary indicators: nutritional indicators (albumin (Alb), prealbumin (PA), serum total protein (TP) level, hemoglobin (HB) level), T cell subsets (CD3+, CD4+, CD8+) and NK cell level, etc.; Safety indicators: liver and kidney function, and skin burns, blisters, and skin damage, etc.

[0055] 3.2 Traditional Chinese Medicine Syndrome Scoring Before and after treatment, the TCM syndrome (fatigue, shortness of breath, insomnia, palpitations, dizziness) was scored. Based on the severity of the symptoms, it was divided into normal (0 points), mild (1 point), moderate (2 points), and severe (3 points). The higher the score, the more severe the patient's symptoms.

[0056] For example: fatigue and weakness: None: no symptoms (0); mild: slightly tired and weak (1); moderate: easily fatigued, weak limbs (2); severe: general weakness, drowsy and reluctant to speak (3) Shortness of breath and reluctance to speak: None: No symptoms (0); Mild: Shortness of breath after activity, and reluctance to talk (1); Moderate: Between mild and severe (2); Severe: Shortness of breath when still, and reluctance to speak (3). Insomnia and palpitations: None: No symptoms (0); Mild: Easy to wake up, difficulty falling asleep, occasional palpitations (1); Moderate: Between mild and severe (2); Severe: Sleepless all night, recurrent palpitations, not relieved by rest (3). Dizziness: None: No symptoms (0); Mild: Occasionally occurs (1); Moderate: Between mild and severe (2); Severe: General weakness, drowsiness and lethargy (3) Symptom score-based efficacy assessment criteria: Ineffective: The reduction in symptom score is less than 20%; Effective: The number of symptoms decreased by ≥20% and <50%; Significant effect: The number of symptom scores decreased by ≥50% and <85%.

[0057] Overall effectiveness = (Number of effective cases + Number of cases with significant effect) / Total number of cases × 100%.

[0058] IV. Statistical Processing

[0059] ; There was no statistically significant difference in albumin levels among the three groups before treatment (p>0.05), indicating comparability. After 1 and 2 months of treatment, albumin levels in all three groups were significantly higher than before treatment (p<0.05). Intergroup comparisons showed that at 1 and 2 months of treatment, albumin levels in groups 2 and 3 were significantly higher than in group 1 (both p<0.05); at 1 month of treatment, albumin levels in group 3 were significantly higher than in group 2 (p=0.0054), while there was no significant difference between the two groups at 2 months of treatment (p>0.05). The results indicate that all three intervention regimens improved the patients' nutritional status, with regimen 3 showing better efficacy in increasing albumin levels in the early stages.

[0060] Table 2 Comparison of hemoglobin levels before and after treatment in the three groups of patients (x±s, g / L)

[0061] There was no statistically significant difference in hemoglobin levels among the three groups before treatment (p>0.05), indicating comparability. After 1 and 2 months of treatment, hemoglobin levels in all three groups were significantly higher than before treatment (p<0.05). Intergroup comparisons showed that at 1 and 2 months of treatment, hemoglobin levels in groups 2 and 3 were significantly higher than in group 1 (both p<0.05); and the hemoglobin level in group 3 was significantly higher than in group 2 (both p<0.05). The results indicate that all three intervention regimens improved the patients' anemia, with regimen 3 showing the best effect.

[0062] Table 3 Comparison of erythrocyte levels before and after treatment in the three groups of patients (x±s, ×10) 12 / L)

[0063] There were no statistically significant differences in erythrocyte levels among the three groups before treatment (p>0.05), indicating comparability. After 1 and 2 months of treatment, erythrocyte levels in all three groups were significantly higher than before treatment (p<0.05). Intergroup comparisons showed that at 1 and 2 months of treatment, erythrocyte levels in groups 2 and 3 were significantly higher than in group 1 (both p<0.05); and the erythrocyte level in group 3 was significantly higher than in group 2 (both p<0.05). The results indicate that all three intervention regimens improved hematopoietic function, with regimen 3 showing the best effect.

[0064] Table 4 Comparison of serum CD4, CD8, and CD3 cell levels before and after treatment in the three groups of patients (x±s, %)

[0065] Before treatment, there were no statistically significant differences in CD3⁺, CD4⁺, CD8⁺, and the CD4⁺ / CD8⁺ ratio among the three groups (p>0.05), indicating comparability. After 1 and 2 months of treatment, the levels of CD3⁺, CD4⁺, and CD8⁺ in all three groups were significantly higher than before treatment (p<0.05). Intergroup comparisons showed that at 1 and 2 months of treatment, the levels of CD3⁺, CD4⁺, and CD8⁺ in groups 2 and 3 were significantly higher than in group 1 (both p<0.05); and the levels of these indicators in group 3 were significantly higher than in group 2 (both p<0.05). The results indicate that all three intervention regimens improved patients' immune function, with regimen 3 showing the best effect.

[0066] Table 5 Comparison of Piper scale levels before and after treatment in the three groups of patients (x±s, %)

[0067] There were no statistically significant differences in Piper scale scores among the three groups before treatment (p>0.05), indicating comparability. After 1 and 2 months of treatment, scores in all three groups decreased compared to pre-treatment levels, and the differences between groups were statistically significant (p<0.05). Pairwise comparisons between groups showed that after treatment, the Piper scale score in group 3 was significantly lower than that in group 1 (both p<0.0001) and group 2 (p=0.0006 at 1 month of treatment and p=0.041 at 2 months of treatment). The results indicate that all three intervention regimens improved cancer-related fatigue, with group 3 showing the best effect.

[0068] Table 6 Comparison of fatigue symptoms before and after treatment in the three groups of patients (x±s, %)

[0069] Table 7 Comparison of symptoms of shortness of breath and reluctance to speak before and after treatment in the three groups of patients (x±s, %)

[0070] Table 8 Comparison of insomnia and palpitation symptoms before and after treatment in the three groups of patients (x±s, %)

[0071] Table 9 Comparison of dizziness and vertigo symptoms before and after treatment in the three groups of patients (x±s, %)

[0072] Table 10 Comparison of symptom efficacy evaluation among the three groups (x±s, %)

[0073] The efficacy evaluation of symptoms in the three groups showed that the total effective rate was 57.50% in group 1, 87.50% in group 2, and 95.00% in group 3. The total effective rates of groups 2 and 3 were significantly higher than those of group 1 (P<0.05). The inter-group effective rate comparison was as follows: group 3 (95%) > group 2 (87.5%) > group 1 (57.50%), with statistically significant differences. The results indicate that the intervention regimens of groups 2 and 3 have significant advantages in improving patient symptoms, and the combined treatment intervention regimen is optimal.

[0074] No toxic side effects were found during the experiment, indicating that the medication is safe and the efficacy is stable and reliable. While conducting the experiment on Example 1, the same or similar experiments were also conducted on other examples, and the same or similar results were obtained. These will not be described in detail here.

[0075] V. Conclusion: Clinical trial results showed that the combination of Shenling Powder and umbilical moxibustion (Group 3) was significantly better than that of the group using Shenling Powder alone (Group 1) and the group using umbilical moxibustion alone (Group 2) in improving albumin, hemoglobin, NK cells, T cell subsets, Piper fatigue scale score, and TCM symptoms (fatigue, shortness of breath, insomnia, palpitations, dizziness) in lung cancer CRF patients (P<0.01). This demonstrates that the combined use of Shenling Powder and umbilical moxibustion (Group 3) has a synergistic effect and is worthy of clinical promotion.

[0076] Furthermore, in this study, the nutritional and hematopoietic function indicators, immune function indicators, Piper fatigue scores, and CRF-related symptoms of the three groups of lung cancer CRF patients all showed a trend of significant improvement in the early stages and gradual improvement in the later stages. Firstly, before treatment, patients' nutritional status, fatigue levels, and symptoms were significantly abnormal. Early intervention directly corrected the most prominent pathological imbalance, causing related indicators to rapidly approach normal ranges. Secondly, when indicators approach physiological thresholds (e.g., albumin within the normal range of 35-55 g / L), the body's self-homeostatic regulation mechanism limits further significant changes in indicators, while the marginal benefit of intervention diminishes, reducing the remaining room for improvement. Additionally, long-term intervention may lead to adaptation or tolerance in the body, also resulting in a decrease in the magnitude of improvement in the later stages. This trend suggests that for clinical intervention of cancer-related fatigue, intensive treatment plans (such as combined drug and moxibustion therapy) can be used in the early stages to rapidly improve symptoms in cancer patients. In the later stages, as the tumor progresses and cancer-related symptoms worsen, strategies need to be adjusted according to the individual patient's condition to overcome improvement bottlenecks and further enhance efficacy.

[0077] In summary, this invention uses abundant raw materials, and the formulation is effectively combined according to the principal and assistant relationships of the ingredients. It is scientific, reasonable, easy to produce and prepare, and convenient to use. It takes the method of nourishing the earth to generate metal as the treatment principle, warms and unblocks the meridians, regulates qi and blood, harmonizes yin and yang, and replenishes essence and marrow. Moreover, it is safe to use, has no toxic side effects, and has good effects with an efficacy rate of over 95%, thus having practical clinical application value.

Claims

1. A combination of moxibustion and medicated medicine for treating cancer-related fatigue in lung cancer, characterized in that, This includes a first-unit oral Chinese medicine composition and a second-unit moxibustion Chinese medicine composition used in combination, wherein: The first unit of the oral Chinese medicine composition is made from the following raw materials by weight: 20-40g of Chinese yam, 15-30g of codonopsis, 15-30g of poria cocos, 20-40g of atractylodes macrocephala, 12-15g of ganoderma lucidum, 10-15g of tangerine peel, 10-20g of white hyacinth bean, 15-20g of lotus seed, 6-12g of prepared licorice root, 6-9g of amomum villosum, 20-30g of coix seed, and 9-15g of platycodon grandiflorus. Combine the above raw materials, add water equal to 5 times their weight, soak for two hours, bring to a boil over high heat, and simmer over low heat for 40 minutes. Take the filtrate, add water equal to 4 times the weight of the raw drug to the residue, bring to a boil over high heat, simmer over low heat for 30 minutes, take the filtrate, combine the two filtrates, concentrate under reduced pressure at 50℃ to prepare an extract with a relative density of 1.2, dry the extract, pulverize it into fine powder, add excipients, the weight ratio of fine powder to excipients is 1:2, the excipients are dextrin and sugar powder in a weight ratio of 1:1, use 80% ethanol as a wetting agent, uniformly form into a soft mass, granulate through a 20-mesh sieve, dry at 60℃, granulate through a 14-mesh sieve, and package to obtain the final product; The second unit of the umbilical moxibustion herbal composition is made from the following raw materials by weight: Astragalus membranaceus 15-30g, Atractylodes macrocephala 10-20g, Saposhnikovia divaricata 10-15g, Alpinia officinarum 6-12g, Zingiber officinale 6-12g, Aucklandia lappa 6-10g, Citrus reticulata 10-15g, Aquilaria sinensis 3-6g, Boswellia carterii 6-10g, and Dalbergia odorifera 6-10g. The above components are pulverized and mixed evenly to form the umbilical moxibustion powder.

2. The combined medicinal and moxibustion drug composition for treating cancer-related fatigue in lung cancer according to claim 1, characterized in that, The first unit of the oral Chinese medicine composition is made from the following raw materials by weight: 30g of Chinese yam, 15g of codonopsis, 15g of poria cocos, 20g of atractylodes macrocephala, 15g of ganoderma lucidum, 15g of tangerine peel, 20g of white hyacinth bean, 15g of lotus seed, 6g of prepared licorice root, 6g of amomum villosum, 20g of coix seed, and 15g of platycodon grandiflorus. The above raw materials are combined, added to 960g of water, soaked for two hours, brought to a boil over high heat, then simmered over low heat for 40 minutes. The filtrate is collected, and the residue is then added to 768g of water. Bring to a boil over high heat, then simmer over low heat for 30 minutes. Collect the filtrate, combine the two filtrates, and concentrate under reduced pressure at 50°C to prepare an extract with a relative density of 1.

2. Dry the extract, pulverize it into a fine powder, and add excipients. The weight ratio of fine powder to excipients is 1:

2. The excipients are dextrin and sugar powder in a weight ratio of 1:

1. Use 80% ethanol as a wetting agent to uniformly form a soft mass, granulate it through a 20-mesh sieve, dry it at 60°C, granulate it through a 14-mesh sieve, and package it to obtain the final product. The second unit of the umbilical moxibustion herbal composition is made from the following raw materials by weight: Astragalus membranaceus 20g, Atractylodes macrocephala 15g, Saposhnikovia divaricata 12g, Alpinia officinarum 9g, Zingiber officinale 9g, Aucklandia lappa 8g, Citrus reticulata 12g, Aquilaria sinensis 5g, Boswellia carterii 8g, and Dalbergia odorifera 8g. The above components are pulverized and mixed evenly to form umbilical moxibustion powder.

3. The combined medicinal and moxibustion drug composition for treating cancer-related fatigue in lung cancer according to claim 1, wherein the first unit, the oral Chinese medicine composition, is made from the following raw materials by weight: 20 g of Dioscorea opposita, 15 g of Codonopsis pilosula, 20 g of Poria cocos, 30 g of Atractylodes macrocephala, 12 g of Ganoderma lucidum, 12 g of Citrus reticulata peel, 15 g of Dolichos lablab, 15 g of Nelumbo nucifera, 9 g of Glycyrrhiza uralensis (processed), 9 g of Amomum villosum, 30 g of Coix lacryma-jobi, and 15 g of Platycodon grandiflorus. The above raw materials are combined, added to 1010 g of water, soaked for two hours, brought to a boil over high heat, simmered over low heat for 40 minutes, and the filtrate is collected. The dregs are then added to 808 g of water, brought to a boil over high heat, and simmered over low heat for 30 minutes. Collect the filtrate, combine the two filtrates, and concentrate under reduced pressure at 50°C to prepare an extract with a relative density of 1.

2. Dry the extract, pulverize it into a fine powder, add excipients, the weight ratio of fine powder to excipients is 1:2, the excipients are dextrin and sugar powder in a weight ratio of 1:1, use 80% ethanol as a wetting agent, uniformly form a soft mass, granulate through a 20-mesh sieve, dry at 60°C, granulate through a 14-mesh sieve, and package to obtain the final product. The second unit of the umbilical moxibustion herbal composition is made from the following raw materials by weight: Astragalus membranaceus 30g, Atractylodes macrocephala 20g, Saposhnikovia divaricata 15g, Alpinia officinarum 12g, Zingiber officinale 12g, Aucklandia lappa 10g, Citrus reticulata 15g, Aquilaria sinensis 6g, Boswellia carterii 10g and Dalbergia odorifera 10g. The above components are pulverized and mixed evenly to form umbilical moxibustion powder.

4. The combined medicated and moxibustion drug composition for treating cancer-related fatigue in lung cancer according to claim 1, wherein the first unit, the oral Chinese medicine composition, is made from the following raw materials by weight: 40g of Dioscorea opposita, 30g of Codonopsis pilosula, 30g of Poria cocos, 40g of Atractylodes macrocephala, 15g of Ganoderma lucidum, 15g of Citrus reticulata peel, 15g of Dolichos lablab, 15g of Nelumbo nucifera, 9g of Glycyrrhiza uralensis (processed), 9g of Amomum villosum, 30g of Coix lacryma-jobi, and 15g of Platycodon grandiflorus. The above raw materials are combined, soaked in 1315g of water for two hours, brought to a boil over high heat, and simmered over low heat for 40 minutes. Take the filtrate, add 1052g of water to the dregs, bring to a boil over high heat, simmer over low heat for 30 minutes, take the filtrate, combine the two filtrates, concentrate under reduced pressure at 50℃ to prepare an extract with a relative density of 1.2, dry the extract, pulverize it into fine powder, add excipients, the weight ratio of fine powder to excipients is 1:2, the excipients are dextrin and sugar powder in a weight ratio of 1:1, use 80% ethanol as a wetting agent, uniformly form into a soft mass, granulate through a 20-mesh sieve, dry at 60℃, granulate through a 14-mesh sieve, and package to obtain the final product; The second unit of the umbilical moxibustion herbal composition is made from the following raw materials by weight: Astragalus membranaceus 15g, Atractylodes macrocephala 10g, Saposhnikovia divaricata 10g, Alpinia galanga 6g, Zingiber officinale 6g, Aucklandia lappa 6g, Citrus reticulata 10g, Aquilaria sinensis 3g, Boswellia carterii 6g and Dalbergia odorifera 6g. The above components are pulverized and mixed evenly to form umbilical moxibustion powder.

5. The combined medicinal and moxibustion drug composition for treating cancer-related fatigue in lung cancer according to claim 1, wherein the first unit, the oral Chinese medicine composition, is made from the following raw materials by weight: 30g of Chinese yam, 20g of codonopsis, 20g of poria cocos, 20g of stir-fried atractylodes macrocephala, 15g of ganoderma lucidum, 15g of tangerine peel, 15g of white hyacinth bean, 15g of lotus seed, 10g of amomum villosum, 30g of stir-fried coix seed, 15g of platycodon grandiflorus, and 9g of prepared licorice root. The above raw materials are combined, soaked in 1070g of water for two hours, brought to a boil over high heat, and simmered over low heat for 40 minutes. Take the filtrate, add 856g of water to the dregs, bring to a boil over high heat, simmer over low heat for 30 minutes, take the filtrate, combine the two filtrates, concentrate under reduced pressure at 50℃ to prepare an extract with a relative density of 1.2, dry the extract, pulverize it into fine powder, add excipients, the weight ratio of fine powder to excipients is 1:2, the excipients are dextrin and sugar powder in a weight ratio of 1:1, use 80% ethanol as a wetting agent, uniformly form a soft mass, granulate through a 20-mesh sieve, dry at 60℃, granulate through a 14-mesh sieve, and package to obtain the final product; The second unit of the umbilical moxibustion herbal composition is made from the following raw materials by weight: Astragalus membranaceus 15g, Atractylodes macrocephala 20g, Saposhnikovia divaricata 10g, Alpinia officinarum 12g, Zingiber officinale 6g, Aucklandia lappa 10g, Citrus reticulata 10g, Aquilaria sinensis 6g, Boswellia carterii 6g and Dalbergia odorifera 10g. The above components are pulverized and mixed evenly to form umbilical moxibustion powder.

6. The combined medicinal and moxibustion drug composition for treating cancer-related fatigue in lung cancer according to claim 1, wherein the first unit, the oral Chinese medicine composition, is made from the following raw materials by weight: 40g of Chinese yam, 15g of codonopsis, 30g of poria cocos, 20g of atractylodes macrocephala, 15g of ganoderma lucidum, 10g of tangerine peel, 20g of white hyacinth bean, 15g of lotus seed, 12g of prepared licorice root, 6g of amomum villosum, 30g of coix seed, and 9g of platycodon grandiflorus. The above raw materials are combined, soaked in 1110g of water for two hours, brought to a boil over high heat, and simmered over low heat for 40 minutes. Take the filtrate, add 888g of water to the dregs, bring to a boil over high heat, simmer over low heat for 30 minutes, take the filtrate, combine the two filtrates, concentrate under reduced pressure at 50℃ to prepare an extract with a relative density of 1.2, dry the extract, pulverize it into fine powder, add excipients, the weight ratio of fine powder to excipients is 1:2, the excipients are dextrin and sugar powder in a weight ratio of 1:1, use 80% ethanol as a wetting agent, uniformly form into a soft mass, granulate through a 20-mesh sieve, dry at 60℃, granulate through a 14-mesh sieve, and package to obtain the final product; The second unit of the umbilical moxibustion herbal composition is made from the following raw materials by weight: Astragalus membranaceus 30g, Atractylodes macrocephala 10g, Saposhnikovia divaricata 15g, Alpinia officinarum 6g, Zingiber officinale 6g, Aucklandia lappa 6g, Citrus reticulata 15g, Aquilaria sinensis 3g, Boswellia carterii 10g and Dalbergia odorifera 6g. The above components are pulverized and mixed evenly to form umbilical moxibustion powder.

7. The use of the medicated moxibustion combined with pharmaceutical composition prepared by the method according to any one of claims 1-6 in the preparation of a drug for treating cancer-related fatigue in lung cancer and a medicine box for treating cancer-related fatigue in lung cancer.

8. The application according to claim 7, characterized in that, The medicine box contains: (a) The traditional Chinese medicine composition in Unit 1 is an oral preparation containing active ingredients; (b) The moxibustion powder made from the traditional Chinese medicine composition of Unit 2; the traditional Chinese medicine composition of Unit 2 also includes flour material for making dough rings, and the dough ring making method described in the instructions for use; (c) Instructions for use, which describe the combined use of the first unit traditional Chinese medicine composition and the second unit traditional Chinese medicine composition, wherein the second unit traditional Chinese medicine composition is used by placing the moxibustion powder on the Shenque acupoint and applying moxibustion.

9. The application according to claim 8, characterized in that, The instruction manual states that the dosage of the moxibustion powder is 10g each time, which is made into moxa cones with a diameter of 2cm and a height of 2cm.

10. The medicinal composition for moxibustion according to any one of claims 1-6, characterized in that, The first unit of traditional Chinese medicine composition can be made into medically acceptable granules, pills, decoctions or capsules according to actual needs; the second unit of traditional Chinese medicine composition can be made into powder, cake or paste.

Images